Anti-retroviral Drugs Market Analysis

Anti-retroviral Drugs Market Analysis

Based on the product, the market is classified into protease inhibitors, integrase inhibitors, multi-class combination products, nucleoside reverse transcriptase inhibitors (NRTIs), non-nucleoside reverse transcriptase inhibitors (NNRTIs), and other drug classes. The multi-class combination products dominated the market with revenue of USD 7.9 billion in 2023.
 

• The segment growth is majorly attributable to the growing burden of HIV and new drug approvals. Additionally, several market players are focusing on development of breakthrough products to maintain their competitive edge and expand in new regional markets.
   
• Furthermore, the growing number of HIV cases worldwide and the efficiency of multiclass combination product medications for its treatment is raising the demand for these drugs, thus driving the segmental growth. For instance, an article published in the journal Nanomaterials in February 2021 described the remarkable outcomes of using multiclass combination product therapy to reduce HIV symptoms. Thus, demand for multiclass combination product is anticipated to impel in the market.
   

Based on type, the anti-retroviral drugs market is classified into branded and generic. The branded segment held the highest business share of 67.2% in 2023.

• The segment is expected to witness significant growth in the forecast period owing to ongoing advancements and innovation in the development, distribution, and utilization of branded antiretroviral drugs, with a focus on improving treatment efficacy, accessibility, and patient outcomes in the management of HIV/AIDS.
   
• Further, the segment's dominance is attributed to widespread use of branded drugs due to their established efficacy, safety profile, and increasing endorsement by healthcare authorities. Adding to this, prominent market competitors are working on creating novel therapies to prevent the transmission of infection.
   

Based on age group, the anti-retroviral drugs market is classified into adult, pediatric, and geriatric. The adult segment is expected to hold the highest revenue throughout the forecast period.
 

• There is increasing recognition of the importance of early initiation of antiretroviral therapy (ART) in adults diagnosed with HIV infection. Initiating ART early, regardless of CD4 cell count, leads to improved clinical outcomes, reduced HIV transmission risk, and decreased morbidity and mortality.
   
• Therefore, increasing need for HIV diagnostics among adult population is anticipated to contribute significantly to the market growth
   

Based on distribution channel, the anti-retroviral drugs market is classified into hospital pharmacy, retail pharmacy, online pharmacy. The hospital pharmacy segment held the highest business share of 43.1% in 2023.
 

• The rising geriatric population, increasing HIV cases, and the increasing number of hospitalizations are the key factors driving the segment expansion.
   
• Further, hospital pharmacies are increasingly integrating HIV services within their facilities, offering comprehensive care for patients living with HIV/AIDS. This integration includes providing antiretroviral therapy (ART), medication management, adherence support, and monitoring of treatment outcomes. Thus, adoption of technologically advanced solutions and employment of specialized HIV pharmacists is anticipated to accelerate the segment progress.
   

In 2023, North America secured a substantial market share in the global anti-retroviral drugs market and is expected to dominate throughout the forecast period.
 

• The factors such as the increasing number of HIV cases, presence of prominent competitors, drug approvals and product launches in the region and technological improvements in drug development will contribute significantly to the market's growth over the projection period.
   
• For instance, according to the World Health Organization in 2022, around 39 million people were living with HIV globally. Thus, a large number of people living with HIV, as well as the increasing prevalence of HIV, are driving demand for anti-retroviral treatments, resulting in the rise of the market in the region.
   

Anti-retroviral Drugs Market Share

The competitive landscape of the market is characterized by the presence of established pharmaceutical companies vying for market share. Key players are engaging in strategic initiatives such as mergers, acquisitions, and partnerships to strengthen their product portfolios. The companies are actively adopting a multi-pronged approaches to address the rising demand for effective anti-retroviral drugs.